Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA.
J Matern Fetal Neonatal Med. 2022 Dec;35(24):4743-4749. doi: 10.1080/14767058.2020.1863364. Epub 2021 Jan 3.
Adequate pain control is a mainstay in enhanced recovery after surgery (ERAS) protocols. ERAS protocols are widely accepted in colorectal and gynecologic surgeries and are increasingly implemented in the obstetric setting. Multimodal analgesia incorporating non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen is a mainstay of ERAS protocols for cesarean delivery, but little research has focused on the choice of NSAIDs or timing of initiation in women undergoing cesarean delivery. At our institution, patients undergoing cesarean delivery receive a standardized multimodal analgesic regimen consisting of neuraxial morphine with NSAIDs and acetaminophen. Our initial protocol involved starting the oral analgesics in the recovery room. There was variability in whether these medications were given in a timely manner or withheld in the setting of postoperative nausea and vomiting. We modified this protocol and performed a retrospective analysis to assess the impact of this change on postoperative opioid rescue requirements in women undergoing cesarean delivery under neuraxial anesthesia.
This retrospective analysis included patients who underwent cesarean deliveries from 1 July 2014 to 22 August 2017. With the initial analgesic protocol, patients received neuraxial morphine, followed by naproxen 500 mg PO Q12 hours and acetaminophen 650-975 mg PO Q6 hours initiated in the recovery room. After protocol revision in January 2016, the same neuraxial morphine dose was used in addition to acetaminophen 975 mg PR at the start of the case and ketorolac 15-30 mg IV at the end of the case. Postoperatively, patients received acetaminophen PO 975 mg Q6 hours, ketorolac IV 15 mg Q6 hours for 3 doses, transitioning to ibuprofen 600 mg Q6 hours. Fentanyl, oxycodone, and intravenous hydromorphone were given for breakthrough pain with both protocols. The primary outcome of the study is the need for rescue opioid analgesia. Secondary outcomes are total opioid usage, time to first rescue opioid, maximum reported pain scores, and need for rescue antiemetics. Univariate and multivariate analyses were performed controlling for variables significantly different between the two cohorts.
3250 patients were included in our analysis (1574 in the old protocol and 1676 in the new protocol). There was no significant difference in patient demographics or intraoperative characteristics between the two cohorts except for more primiparous women (25% vs. 17%), more Pfannenstiel incision (98% vs. 96%), and less repeat cesarean deliveries (40% vs. 44%) in the new protocol cohort. Need for rescue opioids was reduced with the new protocol at 2, 24, and 48 h [(36.46% vs. 75.73%, < .0001), (74.28% vs 91.99%, < .0001), (87.53% vs 95.49% < .0001), respectively]. Among those who received opioids, opioid consumption over 48 h was reduced (median [IQR]: 55 [30, 95] vs. 40 [20, 70] mg oxycodone equivalents) after protocol revision (GMR 0.75, 95% CI 0.7, 0.80, < .0001). The time to first rescue opioid medication was significantly longer in the new protocol compared to the old protocol (175 [79, 1057] min vs 51 [28, 104] min, < .001).
There was a significant decrease in the need for and the dose of rescue opioid medications with the new protocol. This highlights the importance of optimizing the choice of agents, as well as route and timing of administration of the components of the postoperative multimodal analgesic regimen.
充分的疼痛控制是术后加速康复(ERAS)方案的主要内容。ERAS 方案在结肠直肠和妇科手术中被广泛接受,并越来越多地应用于产科。包含非甾体抗炎药(NSAIDs)和对乙酰氨基酚的多模式镇痛是剖宫产中 ERAS 方案的主要内容,但很少有研究关注 NSAIDs 的选择或剖宫产患者开始使用的时间。在我们的机构中,行剖宫产的患者接受标准化的多模式镇痛方案,包括鞘内吗啡联合 NSAIDs 和对乙酰氨基酚。我们最初的方案涉及在恢复室开始口服镇痛药。在术后恶心和呕吐的情况下,这些药物是否及时给予或是否被延迟给予存在差异。我们修改了该方案并进行了回顾性分析,以评估该变化对接受椎管内麻醉剖宫产患者术后阿片类药物解救需求的影响。
这项回顾性分析包括 2014 年 7 月 1 日至 2017 年 8 月 22 日期间行剖宫产的患者。在初始镇痛方案中,患者接受鞘内吗啡,随后在恢复室给予萘普生 500mg PO Q12 小时和对乙酰氨基酚 650-975mg PO Q6 小时。2016 年 1 月方案修订后,在手术开始时给予对乙酰氨基酚 975mg PR 和酮咯酸 15-30mg IV,同时使用相同的鞘内吗啡剂量。术后,患者接受对乙酰氨基酚 PO 975mg Q6 小时,酮咯酸 IV 15mg Q6 小时,共 3 剂,然后转为布洛芬 600mg Q6 小时。两种方案均使用芬太尼、羟考酮和静脉氢吗啡酮治疗爆发性疼痛。本研究的主要结局是需要解救性阿片类药物镇痛。次要结局是总阿片类药物用量、首次解救性阿片类药物的时间、最大报告疼痛评分和需要解救性止吐药的情况。进行了单变量和多变量分析,控制了两个队列之间有显著差异的变量。
共有 3250 名患者纳入分析(旧方案 1574 名,新方案 1676 名)。除初产妇比例较高(25% vs. 17%)、Pfannenstiel 切口比例较高(98% vs. 96%)和再次剖宫产比例较低(40% vs. 44%)外,两组患者的人口统计学和术中特征无显著差异。与旧方案相比,新方案在 2、24 和 48 小时时需要解救性阿片类药物的比例降低(分别为 36.46% vs. 75.73%,<0.0001)、(74.28% vs. 91.99%,<0.0001)、(87.53% vs. 95.49%,<0.0001)。在接受阿片类药物的患者中,方案修订后 48 小时内的阿片类药物消耗减少(中位数[IQR]:55[30,95] vs. 40[20,70]mg 羟考酮当量)(GMR 0.75,95%CI 0.7,0.80,<0.0001)。与旧方案相比,新方案首次解救性阿片类药物用药时间明显延长(175[79,1057]min vs. 51[28,104]min,<0.001)。
新方案显著降低了需要和解救性阿片类药物的剂量。这强调了优化药物选择以及术后多模式镇痛方案中药物的给药途径和时间的重要性。